{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:18:27Z","timestamp":1792592307379,"version":"4.5.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>High-risk subtypes of B-cell acute lymphoblastic leukemia (B-ALL) are frequently associated with aberrant activation of tyrosine kinases (TKs). These include Ph+ B-ALL driven by BCR-ABL, and Ph-like B-ALL that carries other chromosomal rearrangements and\/or gene mutations that activate TK signaling. Currently, the tyrosine kinase inhibitor (TKI) dasatinib is added to chemotherapy as standard of care in Ph+ B-ALL, and TKIs are being tested in clinical trials for Ph-like B-ALL. However, growth factors and nutrients in the leukemia microenvironment can support cell cycle and survival even in cells treated with TKIs targeting the driving oncogene. These stimuli converge on the kinase mTOR, whose elevated activity is associated with poor prognosis. In preclinical models of Ph+ and Ph-like B-ALL, mTOR inhibitors strongly enhance the anti-leukemic efficacy of TKIs. Despite this strong conceptual basis for targeting mTOR in B-ALL, the first two generations of mTOR inhibitors tested clinically (rapalogs and mTOR kinase inhibitors) have not demonstrated a clear therapeutic window. The aim of this review is to introduce new therapeutic strategies to the management of Ph-like B-ALL. We discuss novel approaches to targeting mTOR in B-ALL with potential to overcome the limitations of previous mTOR inhibitor classes. One approach is to apply third-generation bi-steric inhibitors that are selective for mTOR complex-1 (mTORC1) and show preclinical efficacy with intermittent dosing. A distinct, non-pharmacological approach is to use nutrient restriction to target signaling and metabolic dependencies in malignant B-ALL cells. These two new approaches could potentiate TKI efficacy in Ph-like leukemia and improve survival.<\/jats:p>","DOI":"10.3389\/fonc.2023.1162694","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:40:42Z","timestamp":1681450842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Roberta","family":"Buono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneera","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia Chromosome-positive acute lymphoblastic leukemia","volume":"386","author":"Fo\u00e0","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of children's oncology group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.561","article-title":"Ph-like acute lymphoblastic leukemia","volume":"2016","author":"Tran","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia Chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric b-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia Chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/hematology.2022000357","article-title":"Clinical screening for ph-like ALL and the developing role of TKIs","volume":"2022","author":"Tran","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory b-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive b-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278697","article-title":"Therapeutic potential of ruxolitinib and ponatinib in patients with","volume":"106","author":"Niswander","year":"2021","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in b-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0647","article-title":"Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia","volume":"14","author":"Suryani","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A children's oncology group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110221","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): Dose-finding results from the part 1 safety phase","author":"K.","year":"2018","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059335","article-title":"Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)","volume":"8","author":"Nemes","year":"2013","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PloS Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2362","article-title":"Molecular pathways: The eIF4F translation initiation complex-new opportunities for cancer treatment","volume":"23","author":"Malka-Mahieu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00530-y","article-title":"Targeting translation of mRNA as a therapeutic strategy in cancer","volume":"14","author":"Pal","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2888","article-title":"A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with Relapsed\/Refractory acute lymphoblastic leukemia","volume":"21","author":"Daver","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14569","article-title":"A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a children's oncology group study (ADVL1114)","volume":"177","author":"Rheingold","year":"2017","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279520","article-title":"Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium trial (TACL 2014-001)","volume":"107","author":"Tasian","year":"2022","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24261","article-title":"Inhibition of mTORC1\/C2 signaling improves anti-leukemia efficacy of JAK\/STAT blockade in","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24020","article-title":"mTOR inhibition enhances efficacy of dasatinib in","volume":"9","author":"Gotesman","year":"2018","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.23.10070","article-title":"Targeting mTOR globally in cancer: thinking beyond rapamycin","volume":"8","author":"Shor","year":"2009","journal-title":"Cell Cycle"},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.18632\/oncotarget.110","article-title":"Targeting TOR dependence in cancer","volume":"1","author":"Janes","year":"2010","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma","volume":"16","author":"Vu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the envelope in the mTOR pathway: the second generation of inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2662","article-title":"A phase II study to assess the safety and efficacy of the dual mTORC1\/2 inhibitor vistusertib in relapsed, refractory DLBCL","volume":"37","author":"Eyre","year":"2019","journal-title":"Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2526","article-title":"Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: The MANTA phase 2 randomized clinical trial","volume":"5","author":"Schmid","year":"2019","journal-title":"JAMA Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01041-x","article-title":"Phase 1 study of mTORC1\/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","volume":"123","author":"Voss","year":"2020","journal-title":"Br J Cancer."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00448","article-title":"Biomarker-based phase II study of sapanisertib (TAK-228): An mTORC1\/2 inhibitor in patients with refractory metastatic renal cell carcinoma","volume":"6","author":"McGregor","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-021-00813-7","article-title":"Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth","volume":"17","author":"Lee","year":"2021","journal-title":"Nat Chem Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01658","article-title":"Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1, for the treatment of mTORC1-activated tumors","volume":"66","author":"Burnett","year":"2023","journal-title":"J Med Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673213","article-title":"Efficacy of a novel bi-steric mTORC1 inhibitor in models of B-cell acute lymphoblastic leukemia","volume":"11","author":"Lee","year":"2021","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","article-title":"The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia","volume":"86","author":"Cortes","year":"1995","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25008","article-title":"Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01032-5","article-title":"Central nervous system prophylaxis and treatment in acute leukemias","volume":"23","author":"Wu","year":"2022","journal-title":"Curr Treat Opt Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-42118-6_12","article-title":"Fasting and caloric restriction in cancer prevention and treatment","volume":"207","author":"Brandhorst","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"124ra27","DOI":"10.1126\/scitranslmed.3003293","article-title":"Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy","volume":"4","author":"Lee","year":"2012","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arr.2016.10.005","article-title":"Impact of intermittent fasting on health and disease processes","volume":"39","author":"Mattson","year":"2017","journal-title":"Ageing Res Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.12.008","article-title":"Fasting: molecular mechanisms and clinical applications","volume":"19","author":"Longo","year":"2014","journal-title":"Cell Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0504","article-title":"Science-driven nutritional interventions for the prevention and treatment of cancer","volume":"12","author":"Mont\u00e9gut","year":"2022","journal-title":"Cancer Discovery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cmet.2015.05.012","article-title":"A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan","volume":"22","author":"Brandhorst","year":"2015","journal-title":"Cell Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2502-7","article-title":"Fasting-mimicking diet and hormone therapy induce breast cancer regression","volume":"583","author":"Caffa","year":"2020","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2017.01.040","article-title":"Fasting-mimicking diet promotes Ngn3-driven beta-cell regeneration to reverse diabetes","volume":"168","author":"Cheng","year":"2017","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.005","article-title":"Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity","volume":"30","author":"Di Biase","year":"2016","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.cmet.2021.10.008","article-title":"Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape","volume":"33","author":"Salvadori","year":"2021","journal-title":"Cell Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8700","article-title":"Fasting-mimicking diet and markers\/risk factors for aging, diabetes, cancer, and cardiovascular disease","volume":"9","author":"Wei","year":"2017","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-21-0030","article-title":"Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer","volume":"12","author":"Vernieri","year":"2022","journal-title":"Cancer Discovery"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164013","article-title":"Safety and feasibility of fasting-mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment","volume":"13","author":"Valdemarin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41467-020-16243-3","article-title":"Synergistic effect of fasting-mimicking diet and vitamin c against KRAS mutated cancers","volume":"11","author":"Di Tano","year":"2020","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0061-0","article-title":"Fasting and cancer: molecular mechanisms and clinical application","volume":"18","author":"Nencioni","year":"2018","journal-title":"Nat Rev Cancer."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708100105","article-title":"Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy","volume":"105","author":"Raffaghello","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.01.008","article-title":"Starvation, stress resistance, and cancer","volume":"29","author":"Buono","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3689","article-title":"Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition","volume":"6","author":"Caffa","year":"2015","journal-title":"Oncotarget"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25987","article-title":"Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of sorafenib in hepatocellular cancer cells","volume":"233","author":"Lo Re","year":"2018","journal-title":"J Cell Physiol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.016","article-title":"Caloric restriction mimetics enhance anticancer immunosurveillance","volume":"30","author":"Pietrocola","year":"2016","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.22.13954","article-title":"Fasting and differential chemotherapy protection in patients","volume":"9","author":"Raffaghello","year":"2010","journal-title":"Cell Cycle"},{"key":"B83","doi-asserted-by":"publisher","first-page":"988","DOI":"10.18632\/aging.100114","article-title":"Fasting and cancer treatment in humans: A case series report","volume":"1","author":"Safdie","year":"2009","journal-title":"Aging (Albany NY)."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.05.046","article-title":"Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial","volume":"172","author":"Ligorio","year":"2022","journal-title":"Eur J Cancer."},{"key":"B85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nm.4252","article-title":"Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation","volume":"23","author":"Lu","year":"2017","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4259","article-title":"Starving leukemia to induce differentiation","volume":"23","author":"Cheng","year":"2017","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595389","article-title":"Obesity is associated with residual leukemia following induction therapy for childhood b-precursor acute lymphoblastic leukemia","volume":"124","author":"Orgel","year":"2014","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113082","article-title":"Is there a causal relationship between childhood obesity and acute lymphoblastic leukemia","volume":"12","author":"Dushnicky","year":"2020","journal-title":"A Review. Cancers (Basel)."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: A systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2014.00053","article-title":"The role of adipose tissue and obesity in causing treatment resistance of acute lymphoblastic leukemia","volume":"2","author":"Sheng","year":"2014","journal-title":"Front Pediatr"},{"key":"B91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40170-018-0189-0","article-title":"Switch to low-fat diet improves outcome of acute lymphoblastic leukemia in obese mice","volume":"6","author":"Tucci","year":"2018","journal-title":"Cancer Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004018","article-title":"Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial","volume":"5","author":"Orgel","year":"2021","journal-title":"Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060370","article-title":"A combination of cytokines rescues highly purified leukemic CLL b-cells from spontaneous apoptosis in vitro","volume":"8","author":"Ghamlouch","year":"2013","journal-title":"PloS One"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020190","article-title":"Targeting mTOR in acute lymphoblastic leukemia","volume":"8","author":"Simioni","year":"2019","journal-title":"Cells"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1162694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:40:45Z","timestamp":1681450845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1162694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":95,"alternative-id":["10.3389\/fonc.2023.1162694"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1162694","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1162694"}}